Apotex and Grünenthal signal deal for Nebido distribution in Canada
Apotex and Grünenthal have accomplished a licensing settlement that grants Apotex unique Canadian rights to Nebido, a long-acting injectable testosterone undecanoate remedy for male hypogonadism.
The contract will enable Apotex to use for a advertising and marketing authorization and distribute the product within the nation by its branded drug division Searchlight Pharma, as soon as regulatory approval is obtained.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
Grünenthal will obtain upfront and milestone funds, in addition to a margin on product gross sales.
The license builds on an present partnership between Apotex and Grünenthal and helps each corporations’ initiative to broaden affected person entry to therapies in Canada.
Grünenthal acquired the worldwide rights to Nebido in 2022 as a part of its progress technique. The corporate has invested greater than €2 billion in mergers and acquisitions since 2017 to diversify its portfolio and create synergies between manufacturing, provide, logistics and industrial infrastructure.
Searchlight Pharma President Mark Nawacki stated: “This marks an essential step in Apotex’s mission to broaden entry to progressive medicines and advance our function as a Drive for Well being.
“Nebido addresses a acknowledged want in males’s well being and represents our first step into testosterone remedy – opening a significant new therapeutic space for Apotex as we strengthen our model portfolio and broaden our presence in specialty care.”
Grünenthal Chief Industrial Officer Jan Adams stated: “We’re excited to broaden our partnership with Apotex and additional strengthen the model’s world presence. By means of this settlement, we provide a helpful and famend model that may profit folks with testosterone deficiency in Canada.”
Nebido is run by medical doctors each ten to 14 weeks as a long-acting depot injection of testosterone undecanoate. It’s indicated for grownup males with confirmed hypogonadism as a consequence of inadequate testosterone ranges.
In August 2024, Formosa Prescribed drugs signed an unique license settlement with Apotex to commercialize clobetasol propionate ophthalmic suspension 0.05% (APP13007) for reduction and restoration from eye surgical procedure.
